Our study also prompts an appraisal of anticancer drugs with consideration of their impact on immune cells within the tumor microenvironment and provides a rationale for further evaluation of PRMT9 inhibition combined with a PD-1/PD-L1 inhibitor against AML. This evidence concerns the gene PDCD1 and acute myeloid leukemia.